Voyageur Pharma enters distribution deal with Phalanx

Executive Summary

• Voyageur Pharmaceuticals Ltd. has signed a non-exclusive distribution and wholesale agreement with Phalanx Comercializadora e Importadora de Componentes SA DE CV to distribute its barium-based contrast media products in Mexico.
• The agreement follows a non-binding letter of intent announced on June 24, 2025, and marks a strategic expansion into the Mexican healthcare sector and broader Latin American markets.
• Phalanx will lead the registration of Voyageur's products with Mexican health regulatory authorities, leveraging its established distribution network and regulatory expertise.

Key Details

• Parties Involved: Voyageur Pharmaceuticals Ltd. (Canadian public company, TSXV: VM) and Phalanx Comercializadora e Importadora de Componentes SA DE CV (Mexican-based distributor).
• Agreement Type: Non-exclusive distribution and wholesale agreement.
• Product Scope: Barium-based contrast media products.
• Territory: Mexico, with strategic alignment for expansion into key Latin American markets.
• Regulatory Strategy: Phalanx is responsible for registering Voyageur's barium contrast media products with appropriate Mexican health regulatory authorities. Voyageur will provide technical and regulatory support to facilitate approval and market access.
• Strategic Context: This partnership is a key milestone in Voyageur's international growth strategy, aiming to expand its global footprint and access underserved markets with increasing demand for high-quality contrast media.
• Previous Milestone: The agreement follows a non-binding letter of intent announced on June 24, 2025.

Notable Quotes

• "This agreement marks a significant step forward in our commercialization road map. It reflects our continued commitment to expanding global access to our innovative, cost-effective imaging solutions. Latin America is a critical market in our expansion plan, and this partnership lays the groundwork for long-term growth." — Brent Willis, Chief Executive Officer of Voyageur Pharmaceuticals Ltd.